Alana Parrish

Dr. Alana Parrish

Department of Medical Pharmacology and Physiology, School of Medicine, University of Missouri, Columbia, MO 65212, USA

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2003 in Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
Verified
Journal Article
Closed access
MPMarisa D Pulido
Marisa D Pulido
APAlana Parrish
Alana Parrish

22 July 2004 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
HCHui-Ting Chen
Hui-Ting Chen
MNMichael F. Neerman
Michael F. Neerman
APAlana Parrish
Alana Parrish
ESEric E. Simanek
Eric E. Simanek

1 March 2007 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Closed access
PDF file
JCJ. M. Catania
J. M. Catania
GCG. Chen
G. Chen
APAlana Parrish
Alana Parrish
Matrix metalloproteinases (MMPs) are a large family of proteinases that remodel extracellular matrix (ECM) components and cleave a number of cell surface proteins. MMP activity is regulated via a number of mechanisms, including inhibition by tissue inhibitors of metalloproteinases (TIMPs). Originally thought to cleave only ECM proteins, MMP substrates are now known to include signaling molecules (growth factor receptors) and cell adhesion molecules. Recent data suggest a role for MMPs in a number of renal pathophysiologies, both acute and chronic. This review will focus on the expression and localization of MMPs and TIMPs in the kidney, as well as summarizing the current information linking these proteins to acute kidney injury, glomerulosclerosis/tubulointerstitial fibrosis, chronic allograft nephropathy, diabetic nephropathy, polycystic kidney disease, and renal cell carcinoma.

1 October 1995 in Life Sciences
Verified
Journal Article
Closed access
APAlana Parrish
Alana Parrish
AGA.Jay Gandolfi
A.Jay Gandolfi
KBKlaus Brendel
Klaus Brendel

1 April 2008 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Closed access
PDF file
DBDavid P. Basile
David P. Basile
KFKatherine Fredrich
Katherine Fredrich
BCBhadrani Chelladurai
Bhadrani Chelladurai
ELEllen C. Leonard
Ellen C. Leonard
APAlana Parrish
Alana Parrish
Reductions in vascular density occur following acute ischemia-reperfusion (I/R) injury that may predispose the development of chronic kidney disease. The mechanisms mediating vascular loss are not clear but may relate to the lack of effective vascular repair responses. To determine the regulation of the VEGF/VEGFR pathway following I/R injury, male Sprague-Dawley rats were subjected to bilateral renal ischemia (45 min) and allowed to recover for 1, 3, 7, and 35 days. VEGF mRNA expression was repressed by greater than 50% of control values up to 3 days postischemia, while VEGF protein was repressed for up to 7 days postischemia. The renal mRNA expression of receptors was not altered postischemia; however, VEGFR1 (flt-1) protein was transiently reduced in kidney while soluble flt-1 was elevated in plasma at 7 days following injury. Microarray analysis of angiogenesis-related genes identified the enhanced expression of a number of genes, among these was ADAMTS-1 (a disintegrin and metalloproteinase with thrombospondin motif-1), a secreted VEGF inhibitor. The altered expression of ADAMTS-1 was confirmed using RT-PCR and Western blot analysis; immunofluorescence localized its expression to proximal tubules following I/R injury. Other genes identified using microarray included aminopeptidase N, Smad-1, and Id-3 and their localization was also examined using immunohistochemistry. In summary, the data indicate no clear pattern of anti-angiogenic gene expression following renal I/R injury. However, the studies do suggest an overall inhibition of the VEGF pathway during the early injury and repair phase of renal ischemia that may contribute to an overall reduction in renal microvascular density.

1 August 2004 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MNMichael F. Neerman
Michael F. Neerman
WZWen Zhang
Wen Zhang
APAlana Parrish
Alana Parrish
ESEric E. Simanek
Eric E. Simanek